{"id":1020,"date":"2026-05-07T04:21:45","date_gmt":"2026-05-07T04:21:45","guid":{"rendered":"https:\/\/ulemnrme.a2hosted.com\/wordpress\/?page_id=1020"},"modified":"2026-05-07T04:22:05","modified_gmt":"2026-05-07T04:22:05","slug":"transcend-t2d-3","status":"publish","type":"page","link":"https:\/\/diaendo.com\/index.php\/transcend-t2d-3\/","title":{"rendered":"TRANSCEND-T2D-3 \u2014 Retatrutide"},"content":{"rendered":"

[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_hdr{background-color: #149d79 !important; padding-top: 28px !important; padding-bottom: 24px !important;}\u201d][vc_column][vc_custom_heading text=\u201dCurrently Recruiting \u00b7 Clinical Research\u201d font_container=\u201dtag:p|font_size:11px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dTRANSCEND-T2D-3 \u2014 Retatrutide in T2D with Renal Impairment\u201d font_container=\u201dtag:h1|font_size:36px|text_align:left|color:%23ffffff|line_height:1.15\u2033 use_theme_fonts=\u201dyes\u201d][vc_custom_heading text=\u201dInvestigating the efficacy and safety of Retatrutide \u2014 a novel triple incretin-hormone agonist \u2014 in adults with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin.\u201d font_container=\u201dtag:p|font_size:15px|text_align:left|color:%23ffffff\u201d use_theme_fonts=\u201dyes\u201d][\/vc_column][\/vc_row]<\/p>\n

[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_intro{background-color: #ffffff !important; padding-top: 20px !important; padding-bottom: 4px !important;}\u201d][vc_column][vc_column_text]<\/p>\n

\u2190 Back to Clinical Research<\/a> \u00b7 Sponsor:<\/strong> Eli Lilly \u00b7 Duration:<\/strong> ~14 months \u00b7 up to 22 visits \u00b7 ClinicalTrials.gov:<\/strong> NCT06297603<\/a><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n

[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_s1{background-color: #ffffff !important; padding-top: 24px !important; padding-bottom: 48px !important;}\u201d][vc_column][vc_column_text]<\/p>\n

About This Study<\/p>\n

[\/vc_column_text][vc_column_text]<\/p>\n

What is being studied?<\/p>\n

\n

This study evaluates the efficacy and safety of Retatrutide<\/strong> at doses of 4 mg, 9 mg, or 12 mg administered once weekly for 52 weeks, compared with placebo, in participants with Type 2 Diabetes and renal impairment whose blood sugar is inadequately controlled on basal insulin alone or basal insulin combined with metformin and\/or an SGLT2 inhibitor.<\/p>\n

Retatrutide is a novel triple incretin-hormone agonist<\/strong>, acting at the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Earlier-phase studies have shown high efficacy in the treatment of obesity, Type 2 Diabetes, and non-alcoholic fatty liver disease.<\/p>\n<\/div>\n

[\/vc_column_text][vc_column_text]<\/p>\n

How does this fit with current medications?<\/p>\n

\n\n\n\n\n\n\n\n
Medication<\/th>\nReceptor activity<\/th>\n<\/tr>\n<\/thead>\n
Semaglutide (Ozempic)<\/td>\nSingle agonist \u2014 GLP-1<\/td>\n<\/tr>\n
Tirzepatide (Mounjaro)<\/td>\nDual agonist \u2014 GIP + GLP-1<\/td>\n<\/tr>\n
Retatrutide (investigational)<\/td>\nTriple agonist \u2014 GIP + GLP-1 + glucagon<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The renal-impairment population is particularly important because patients with reduced kidney function have historically had fewer treatment options and are at higher risk of complications from poor glycemic control. This study is designed to provide rigorous data in exactly that group.<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n

[vc_row full_width=\u201dstretch_row\u201d css=\u201d.vc_custom_tt_s2{background-color: #f5f7f6 !important; padding-top: 24px !important; padding-bottom: 48px !important;}\u201d][vc_column][vc_column_text]<\/p>\n

Eligibility Criteria<\/p>\n

[\/vc_column_text][vc_column_text]<\/p>\n

Who can participate?<\/p>\n

\n

Eligibility is determined at a screening visit. Final inclusion is confirmed only after a full review of the protocol-mandated criteria.<\/p>\n<\/div>\n

[\/vc_column_text][vc_row_inner][vc_column_inner width=\u201d1\/2\u2033][vc_column_text]<\/p>\n

\n

Key Inclusion Criteria<\/h4>\n